FDA Hands Fast-Pass Voucher for Bizarre Rare Kid Disease Drug
Published Date: 1/21/2026
Notice
Summary
The FDA just gave a special fast-track ticket called a Priority Review Voucher to UCB, Inc. for their rare pediatric disease drug KYGEVVI, approved in November 2025. This voucher helps speed up future drug reviews, saving time and potentially money for the company. It’s a big win for patients with thymidine kinase 2 deficiency and a boost for UCB’s innovation efforts.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
KYGEVVI Approved for TK2 Deficiency
KYGEVVI (doxecitine and doxribtimine) was approved November 3, 2025, to treat thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients whose symptoms began at age 12 years or younger. The approval covers both adult patients and pediatric-onset cases with symptom onset on or before 12 years.
Priority Review Voucher Issued to UCB
The FDA issued a Rare Pediatric Disease Priority Review Voucher to the sponsor of KYGEVVI (doxecitine and doxribtimine). KYGEVVI was approved November 3, 2025, and the voucher is now formally awarded under section 529 of the FD&C Act.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11739 — Medical Devices; Immunology and Microbiology Devices; Classification of the Simple Point-of-Care Device to Directly Detect SARS-CoV-2 Viral Targets From Clinical Specimens in Near-Patient Settings
The FDA is officially putting simple COVID-19 rapid test devices into a safer, easier-to-manage category called Class II. This change means these tests can get to patients faster and with fewer hoops to jump through, while still making sure they work well and stay safe. Starting June 11, 2026, companies making these tests will follow new rules that help speed up innovation without extra costs.
2026-11740 — Medical Devices; Immunology and Microbiology Devices; Classification of the Spinal Muscular Atrophy Newborn Screening Test System
The FDA is officially putting the Spinal Muscular Atrophy (SMA) newborn screening test into class II, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps make the test safer and easier to get to babies who need it, starting June 11, 2026, with the classification effective since November 2022. Labs and device makers will benefit from clearer rules and faster access, helping catch SMA early without extra costs or delays.
2026-11760 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Establishment, Maintenance, and Availability of Records; Additional Traceability Records for Certain Foods
The FDA is asking for approval to collect extra records from food businesses that handle certain high-risk foods. This helps track food sources quickly to keep everyone safe. Food companies should get ready to keep and share these new records, and comments on this plan are due by July 13, 2026.
2026-11762 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Procedures for the Safe Processing and Importing of Fish and Fishery Products
The FDA is asking for approval to keep collecting info from seafood processors and importers to make sure fish products are safe using a system called HACCP. This affects anyone who processes or imports fish and requires them to keep records showing they’re following safety rules. Comments on this plan are open until July 13, 2026, and there’s no new cost, just a continuation of current paperwork.
2026-11589 — Medical Devices; Ear, Nose, and Throat Devices; Classification of the Combined Acoustic and Electrical External Stimulation Device for the Relief of Tinnitus
The FDA has officially placed the combined acoustic and electrical external stimulation device for tinnitus relief into class II, meaning it now has special safety rules but fewer regulatory hurdles. This change helps patients get access to this innovative device faster and ensures it’s safe and effective. The new classification is effective June 10, 2026, with the rules applying retroactively from March 6, 2023.
2026-11578 — Amending Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use, and Related Information
The FDA just gave a thumbs-up to adding bemotrizinol as a new active ingredient in sunscreens, letting it be used up to 6% concentration. This means sunscreen makers can now include this ingredient, which is safe and effective, in their products. The change is official as of June 10, 2026, and could lead to better sun protection options without extra costs for consumers.
Previous / Next Documents
Previous: 2026-01063 — Information Collection Being Reviewed by the Federal Communications Commission Under Delegated Authority
The FCC is checking in on a paperwork process that helps businesses and nonprofits sort out application conflicts. They want your thoughts on how to make this easier and clearer, especially for small businesses. Comments are open until March 23, 2026, so don’t miss your chance to weigh in and help save time and hassle!
Next: 2026-01067 — Advisory Committee on the Readjustment of Veterans, Notice of Meeting
The Advisory Committee on the Readjustment of Veterans will meet online on March 24, 2026, to review their latest report and plan future meetings. This group helps the VA improve benefits and services for Veterans adjusting to civilian life, especially those who served in combat. The public can join, share comments, and help shape how Veterans get support—no money changes announced, but your voice matters!